CpG-insel-hypermethylierung der DNA: Perspektiven eines molekularen biomarkers für das prostatakarzinom

Translated title of the contribution: CpG island hypermethylation of the DNA: Perspectives of a molecular biomarker for prostate cancer

P. J. Bastian, J. Ellinger, A. Von Rücker, S. C. Müller, S. Yegnasubramanian, W. G. Nelson, C. G. Stief

Research output: Contribution to journalArticlepeer-review

Abstract

The exact classification of clinically significant versus insignificant prostate cancer displays one of major problems in current urological practice. Using novel molecular biomarkers, we are trying to decrease overdiagnosis of insignificant cancer. CpG island hypermethylation as a common epigenetic event is a well-recognized phenomenon during carcinogenesis. We have shown that hypermethylation at several gene loci distinguishes between benign and malignant forms of prostatic disorders. Furthermore using tests in cancer tissue and serum samples, one can draw prognostic conclusions and predict biochemical failure following radical prostatectomy with curative intent.

Translated title of the contributionCpG island hypermethylation of the DNA: Perspectives of a molecular biomarker for prostate cancer
Original languageGerman
Pages (from-to)1205-1207
Number of pages3
JournalUrologe - Ausgabe A
Volume47
Issue number9
DOIs
StatePublished - Sep 1 2008

Keywords

  • Biomarker
  • CpG island
  • GSTP1
  • Methylation
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'CpG island hypermethylation of the DNA: Perspectives of a molecular biomarker for prostate cancer'. Together they form a unique fingerprint.

Cite this